Medical Device Firm Bioventus Stock Jumps On Upbeat 2025 Outlook, Cuts Debt By $48 Million
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 11 2025
0mins
Source: Benzinga
Financial Performance: Bioventus Inc reported a fourth-quarter adjusted EPS of 15 cents, exceeding expectations, with sales of $153.6 million reflecting a 13.5% year-over-year increase driven by growth in pain treatments and surgical solutions.
Future Outlook: The company anticipates 2025 sales between $560 million and $570 million, along with an adjusted EPS forecast of $0.64-$0.68, indicating positive growth despite the divestiture of its Advanced Rehabilitation Business.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BVS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BVS
Wall Street analysts forecast BVS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BVS is 15.00 USD with a low forecast of 15.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 7.820
Low
15.00
Averages
15.00
High
15.00
Current: 7.820
Low
15.00
Averages
15.00
High
15.00
About BVS
Bioventus Inc. is a medical device company. The Company’s portfolio of products is grouped into three areas. Its Pain Treatments include the Knee Osteoarthritis (KOA) area, and Peripheral Nerve Stimulation (PNS) area. Its Surgical Solutions include Ultrasonics, which offers precision bone resection for patients with degenerative spine conditions and spinal deformities, and Bone Graft Substitutes (BGS), which includes a range of products that facilitate optimal bone fusion following a surgical procedure. Its Restorative Therapies comprise Fracture Care that provide low-intensity pulse ultrasound to help patients who suffer from bone fractures that do not heal through traditional methods. It offers a diverse portfolio of products to support physicians in relieving pain and addressing musculoskeletal challenges across indications and clinical areas, including knee, hand and upper extremities, foot and ankle, podiatry, trauma, general surgery, spine and neurosurgery.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Bravura Solutions Projects FY2026 Revenue of A$265-275 Million Amid Insider Buying
- Company Overview: Bravura Solutions, a software provider specializing in wealth management and insurance services, has a market cap of A$0.20 billion and projects FY2026 revenue between A$265 million and A$275 million, indicating robust growth potential in the market.
- Revenue Sources: The company generates revenue primarily from the EMEA and APAC regions, contributing A$186.07 million and A$72.63 million respectively, while facing challenges with fluctuating cost of goods sold, as evidenced by a recent gross profit margin of 43.20%.
- Insider Confidence: Director Russell Baskerville purchased 40,000 shares for A$92,400 in November 2025, reflecting strong confidence in the company's future despite its reliance on external borrowing for funding.
- Leadership Changes: Baskerville's recent appointment as Chair may bring new strategic direction to the company, helping it seize growth opportunities amidst evolving market dynamics.
Continue Reading
BioVersys Initiates BV100 Phase 3 Clinical Trial, Raises CHF 76.7 Million in IPO
- Phase 3 Trial Launch: BioVersys initiated the BV100 Phase 3 clinical trial in December 2025, with preliminary data expected in H2 2027, marking a significant advancement in the fight against drug-resistant bacterial infections.
- Successful IPO Financing: The company completed its IPO on the SIX Swiss Exchange in February 2025, raising CHF 76.7 million, which significantly extends its cash runway to 2028, supporting the BV100 Phase 3 trial and other R&D projects.
- Global Collaboration Expansion: BioVersys entered into a global research collaboration with Japanese pharmaceutical company Shionogi to advance the BV500 program, which aims to provide new treatment options for approximately 250,000 patients affected by NTM infections annually, enhancing the company's market competitiveness.
- Diversified Clinical Trials: The Phase 2b trial for BV100 received funding from Wellcome and is expected to start in H1 2026, aiming to provide real-world evidence that enhances the company's clinical practice capabilities in high-resistance environments.
Continue Reading